ArticleClinical cancer research : an official journal of the American Association for Cancer Research2015
Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04239105 (Detection and Analysis of Circulating Tumor Cells), which is not on this map. Cited by 154 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Detection and Analysis of Circulating Tumor Cells (CTCs) in Patients With Breast Cancer Using a Novel Microfluidic and Raman Spectrum Device
Who cites it
154 citing papers in PubMed, 3 syntheses or guidelines pooled it, 245 citations in OpenAlex.
- Prognostic significance of blood-based PD-L1 analysis in patients with non-small cell lung cancer undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis.World journal of surgical oncology · 2023Pooled it
- Prognostic value of epithelial-mesenchymal transition circulating tumor cells in female breast cancer: A meta-analysis.Frontiers in oncology · 2022Pooled it
- Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.Cancer medicine · 2021Pooled it
- Intravenous 5-fluoro-2'-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors.Cancer chemotherapy and pharmacology · 2020Trial
- The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.Cancer communications (London, England) · 2019Trial
- Tumor-Derived Extracellular Vesicles in Plasma for Predicting Anti-PD-1 Antibody Efficacy in Non-Small Cell Lung Cancer.Cancer science · 2026Article
- The "Hit-and-Run" legacy: epigenetic locking and the survival switch in H. pylori-associated gastric cancer.Cell death discovery · 2026Review
- Characterization of a distinct form of vimentin in the neurodegenerative brain.Acta neuropathologica communications · 2026Article
- Diagnostic and Prognostic Utility of Cell-Surface Vimentin Positive Circulating Tumor Cells in Breast Cancer Using an Automated Negative Selection Platform.Diseases (Basel, Switzerland) · 2026Article
- Circulating Tumor Cells: Isolation, Preclinical Models, and Clinical Applications for Personalized Cancer Therapy.Biomolecules · 2026Review
- Circulating tumor cells (CTCs) enumeration and machine-learning based diagnostic biomarkers for breast cancer detection.BMC cancer · 2026Article
- Longitudinal monitoring of circulating tumor cell phenotypic conversion as a predictor of late recurrence in breast cancer: a prospective feasibility study using the GenoCTC platform.Frontiers in oncology · 2026Article
- Characterizing epithelial-mesenchymal transition-linked heterogeneity in breast cancer circulating tumor cells at a single-cell level.Molecular oncology · 2025Article
- Novel CTC Detection Method in Patients with Pancreatic Cancer Using High-Resolution Image Scanning.Cancers · 2025Article
- Targeting and Suppression of Survivin in Cancer Cells Based on the Interaction of Cell Surface Vimentin withACS omega · 2025Article
- Precision Oncology Framework Using Circulating Tumor Cells.International journal of molecular sciences · 2025Review
- Matrix metalloproteinase-driven epithelial-mesenchymal transition: implications in health and disease.Journal of translational medicine · 2025Review
- Multifaceted Approaches in Epithelial Cell Adhesion Molecule-Mediated Circulating Tumor Cell Isolation.Molecules (Basel, Switzerland) · 2025Review
- Advanced Detection of Pancreatic Cancer Circulating Tumor Cells Using Biomarkers and Magnetic Particle Spectroscopy.Nanotheranostics · 2025Article
- The correlation between epithelial-mesenchymal transition classification and MMP2 expression of circulating tumor cells and prognosis of advanced or metastatic nasopharyngeal carcinoma.Open medicine (Warsaw, Poland) · 2025Article
94 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
purposeThis study aimed to detect cell-surface vimentin (CSV) on the surface of epithelial-mesenchymal transitioned (EMT) circulating tumor cells (CTC) from blood of patients with epithelial cancers. EXPERIMENTAL
designIn this study, 101 patients undergoing postsurgery adjuvant chemotherapy for metastatic colon cancer were recruited. EMT CTCs were detected from blood of patients using the 84-1 monoclonal antibody against CSV as a marker. EMT CTCs isolated were characterized further using EMT-specific markers, fluorescent in situ hybridization, and single-cell mutation analysis.
resultsUsing the 84-1 antibody, we detected CSV exclusively on EMT CTCs from a variety of tumor types but not in the surrounding normal cells in the blood. The antibody exhibited very high specificity and sensitivity toward different epithelial cancer cells. With this antibody, we detected and enumerated EMT CTCs from patients. From our observations, we defined a cutoff of <5 or ≥5 EMT CTCs as the optimal threshold with respect to therapeutic response using ROC curves. Using this defined threshold, the presence of ≥5 EMT CTCs was associated with progressive disease, whereas patients with <5 EMT CTCs showed therapeutic response.
conclusionTaken together, the number of EMT CTCs detected correlated with the therapeutic outcome of the disease. These results establish CSV as a universal marker for EMT CTCs from a wide variety of tumor types and thus provide the foundation for emerging CTC detection technologies and for studying the molecular regulation of these EMT CTCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.